Per Stål - Concepedia

Author

Per Stål

Karolinska University Hospital ORCID

Also Known As

L Lo o f, M Dodd, P STAL, P Stal, P Stål, P. STÅL, P. Stal, P. Stål, P. Stål, G. Lindberg, å. Öst, M. Iw, P.I. Stal

210

Publications

14.2K

Citations

H-Index

127

Concepts

All Affiliations

Karolinska University Hospital Karolinska Institutet Linköping University Uppsala University Hospital Sahlgrenska University Hospital

About

Per Stål is an author at Karolinska University Hospital specializing in medicine, hepatology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	28	6K
2	Health Sciences	15	16	4.2K
3	Public Health	4	4	207
4	Applied Physiology	2	2	98
5	Anatomy	1	1	49

Per Stål

Publications

11.8K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Andrew X. Zhu, Richard S. Finn, Julien Edeline, The Lancet Oncology Open-label Phase 2HepatologyMedicineClinical TrialsPathology	2018	2.5K
Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Hepatology	2014	2.2K
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Journal of Hepatology FibrosisMetabolic Associated SteatohepatitisHepatologyBiopsy-proven NafldNonalcoholic Fatty Liver Disease	2017	1K
Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up Cecilia Söderberg, Per Stål, Johan Askling, Hepatology	2009	747
Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Hepatology Communications	2017	296
Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives Maria Elmberg, Rolf Hultcrantz, Anders Ekbom, Gastroenterology Hereditary HemochromatosisFirst-degree RelativesCancer RiskGenetic DisorderMedicine	2003	271
A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis Soo Aleman, Nogol Rahbin, Ola Weiland, Clinical Infectious Diseases	2013	232
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial Magnus Holmer, Catarina Lindqvist, Sven Petersson, JHEP Reports	2021	203
Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease Hannes Hagström, Patrik Nasr, Mattias Ekstedt, Clinical Gastroenterology and Hepatology Metabolic SyndromeLiver-related EndpointsMetabolic Associated SteatohepatitisHepatologyCardiovascular Disease	2018	118

Page 1